{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T01:34:29Z","timestamp":1792892069570,"version":"4.5.0"},"reference-count":115,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T00:00:00Z","timestamp":1668470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Fibroblast growth factor 21 (FGF21), a member of fibroblast growth factor family, is a hormone-like growth factor that is synthesized mainly in the liver and adipose tissue. FGF21 regulates lipid and glucose metabolism and has substantial roles in decreasing lipogenesis and increasing hepatic insulin sensitivity which causing lipid profile improvement. FGF21 genetic variations also affect nutritional and addictive behaviors such as smoking and alcohol consumption and eating sweets. The role of FGF21 in metabolic associated diseases like diabetes mellitus had been confirmed previously. Recently, several studies have demonstrated a correlation between FGF21 and liver diseases. Non-alcoholic fatty liver disease (NAFLD) is the most prevalent type of chronic liver disease worldwide. NAFLD has a wide range from simple steatosis to steatohepatitis with or without fibrosis and cirrhosis. Elevated serum levels of FGF21 associated with NAFLD and its pathogenesis. Alcoholic fatty liver disease (AFLD), another condition that cause liver injury, significantly increased FGF21 levels as a protective factor; FGF21 can reverse the progression of AFLD and can be a potential therapeutic agent for it. Also, NAFLD and AFLD are the most important risk factors for hepatocellular carcinoma (HCC) which is the fourth deadliest cancer in the world. Several studies showed that lack of FGF21 induced oncogenic condition and worsened HCC. In this review article, we intend to discuss different aspects of FGF21 in NAFLD, AFLD and HCC; including the role of FGF21 in pathophysiology of these conditions, the effects of FGF21 mutations, the possible use of the FGF21 as a biomarker in different stages of these diseases, as well as the usage of FGF21 and its analog molecules in the treatment of these diseases.<\/jats:p>","DOI":"10.3389\/fmed.2022.967375","type":"journal-article","created":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T01:12:46Z","timestamp":1668474766000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":94,"title":["The role of FGF21 and its analogs on liver associated diseases"],"prefix":"10.3389","volume":"9","author":[{"given":"Kimia","family":"Falamarzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahdi","family":"Malekpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mobin Fallah","family":"Tafti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Negar","family":"Azarpira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrdad","family":"Behboodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Zarei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s13105-019-00675-7","article-title":"FGF19 subfamily members: FGF19 and FGF21","volume":"75","author":"Dolegowska","year":"2019","journal-title":"J Physiol Biochem."},{"key":"B2","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1055\/a-0879-2968","article-title":"Circulating FGF21 levels in human health and metabolic disease","volume":"128","author":"Keuper","year":"2019","journal-title":"Exp Clin Endocrinol Diab."},{"key":"B3","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/s42255-021-00354-2","article-title":"Metabolic messengers: FGF21","volume":"3","author":"Flippo","year":"2021","journal-title":"Nat Metab."},{"key":"B4","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/s41574-020-0386-0","article-title":"The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic","volume":"16","author":"Geng","year":"2020","journal-title":"Nat Rev Endocrinol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"419","DOI":"10.3389\/fphys.2019.00419","article-title":"FGF21 as modulator of metabolism in health and disease","volume":"10","author":"Tezze","year":"2019","journal-title":"Front Physiol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/nrendo.2016.206","article-title":"FGF21 and metabolic disease in 2016: a new frontier in FGF21 biology","volume":"13","author":"Potthoff","year":"2017","journal-title":"Nat Rev Endocrinol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11154-019-09488-x","article-title":"The roles of FGF21 in atherosclerosis pathogenesis","volume":"20","author":"Tabari","year":"2019","journal-title":"Rev Endocr Metab Disord."},{"key":"B8","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.atherosclerosis.2020.03.009","article-title":"Relationship of fibroblast growth factor 21 levels with inflammation, lipoproteins and non-alcoholic fatty liver disease","volume":"299","author":"Tucker","year":"2020","journal-title":"Atherosclerosis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/cts.12839","article-title":"Evolving role for pharmacotherapy in NAFLD\/NASH","volume":"14","author":"Attia","year":"2021","journal-title":"Clin Transl Sci."},{"key":"B10","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1080\/13543784.2020.1718104","article-title":"Fibroblast growth factor (FGF)-21 based therapies: a magic bullet for nonalcoholic fatty liver disease (NAFLD)?","volume":"29","author":"Ritchie","year":"2020","journal-title":"Expert Opin Investig Drugs."},{"key":"B11","doi-asserted-by":"publisher","first-page":"264","DOI":"10.14218\/JCTH.2017.00056","article-title":"Future pharmacotherapy for non-alcoholic steatohepatitis (NASH): review of phase 2 and 3 trials","volume":"6","author":"Connolly","year":"2018","journal-title":"J Clin Transl Hepatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1016\/S0140-6736(18)31785-9","article-title":"Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial","volume":"392","author":"Sanyal","year":"2018","journal-title":"Lancet."},{"key":"B13","doi-asserted-by":"publisher","first-page":"601290","DOI":"10.3389\/fendo.2020.601290","article-title":"FGF21: an emerging therapeutic target for non-alcoholic steatohepatitis and related metabolic diseases","volume":"11","author":"Tillman","year":"2020","journal-title":"Front Endocrinol (Lausanne)."},{"key":"B14","doi-asserted-by":"publisher","first-page":"30484","DOI":"10.1038\/srep30484","article-title":"Fibroblast growth factor 21 reflects liver fat accumulation and dysregulation of signalling pathways in the liver of C57BL\/6J mice","volume":"6","author":"Rusli","year":"2016","journal-title":"Sci Rep."},{"key":"B15","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2478\/jtim-2019-0029","article-title":"Role of hepatokines in non-alcoholic fatty liver disease","volume":"7","author":"Ke","year":"2019","journal-title":"J Transl Int Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1530\/EC-20-0152","article-title":"FGF21 regulates hepatic metabolic pathways to improve steatosis and inflammation","volume":"9","author":"Keinicke","year":"2020","journal-title":"Endocr Connect."},{"key":"B17","first-page":"4750","article-title":"An engineered FGF21 variant, LY2405319, can prevent non-alcoholic steatohepatitis by enhancing hepatic mitochondrial function","volume":"8","author":"Lee","year":"2016","journal-title":"Am J Transl Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s11010-016-2774-2","article-title":"FGF21 ameliorates nonalcoholic fatty liver disease by inducing autophagy","volume":"420","author":"Zhu","year":"2016","journal-title":"Mol Cell Biochem."},{"key":"B19","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.cytogfr.2017.08.001","article-title":"Rush to the fire: FGF21 extinguishes metabolic stress, metaflammation and tissue damage","volume":"38","author":"Luo","year":"2017","journal-title":"Cytokine Growth Factor Rev."},{"key":"B20","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/s41575-019-0145-7","article-title":"From NASH to HCC: current concepts and future challenges","volume":"16","author":"Anstee","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"4300","DOI":"10.3748\/wjg.14.4300","article-title":"Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis","volume":"14","author":"Gomaa","year":"2008","journal-title":"World J Gastroenterol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s13045-019-0806-6","article-title":"Tumorigenesis, diagnosis, and therapeutic potential of exosomes in liver cancer","volume":"12","author":"Wang","year":"2019","journal-title":"J Hematol Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1111\/liv.15100","article-title":"High serum fibroblast growth factor 21 is associated with inferior hepatocellular carcinoma survival: a prospective cohort study","volume":"42","author":"Liu","year":"2021","journal-title":"Liver Int."},{"key":"B24","doi-asserted-by":"publisher","first-page":"16482","DOI":"10.1038\/s41598-017-16312-6","article-title":"Diverse changes of circulating fibroblast growth factor 21 levels in hepatitis B virus-related diseases","volume":"7","author":"Wu","year":"2017","journal-title":"Sci Rep."},{"key":"B25","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/1471-230X-13-67","article-title":"Activation of Liver FGF21 in hepatocarcinogenesis and during hepatic stress","volume":"13","author":"Yang","year":"2013","journal-title":"BMC Gastroenterol."},{"key":"B26","first-page":"1011","article-title":"Lack of fibroblast growth factor 21 accelerates metabolic liver injury characterized by steatohepatities in mice","volume":"6","author":"Liu","year":"2016","journal-title":"Am J Cancer Res."},{"key":"B27","first-page":"1762","article-title":"Loss of FGF21 in diabetic mouse during hepatocellular carcinogenetic transformation","volume":"5","author":"Zhang","year":"2015","journal-title":"Am J Cancer Res."},{"key":"B28","first-page":"606","article-title":"FGF21 inhibits lipid accumulation and inflammation induced by palmitate in human hepatocytes via SIRT1 pathway","volume":"35","author":"Nan","year":"2019","journal-title":"Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi."},{"key":"B29","doi-asserted-by":"publisher","first-page":"9923","DOI":"10.7150\/thno.45988","article-title":"Lack of FGF21 promotes NASH-HCC transition via hepatocyte-TLR4-IL-17A signaling","volume":"10","author":"Zheng","year":"2020","journal-title":"Theranostics."},{"key":"B30","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1002\/mc.20241","article-title":"Forced expression of hepatocyte-specific fibroblast growth factor 21 delays initiation of chemically induced hepatocarcinogenesis","volume":"45","author":"Huang","year":"2006","journal-title":"Mol Carcinog."},{"key":"B31","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jhep.2018.09.014","article-title":"Burden of liver diseases in the world","volume":"70","author":"Asrani","year":"2019","journal-title":"J Hepatol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1093\/abbs\/gmu097","article-title":"FGF21 treatment ameliorates alcoholic fatty liver through activation of AMPK-SIRT1 pathway","volume":"46","author":"Zhu","year":"2014","journal-title":"Acta Biochim Biophys Sin (Shanghai)."},{"key":"B33","first-page":"1778","article-title":"Therapeutic effect of fibroblast growth factor 21 on NAFLD in MSG-iR mice and its mechanism","volume":"48","author":"Zhu","year":"2013","journal-title":"Yao Xue Xue Bao."},{"key":"B34","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.cmet.2016.02.001","article-title":"A long-acting FGF21 molecule, PF-05231023, decreases body weight and improves lipid profile in non-human primates and type 2 diabetic subjects","volume":"23","author":"Talukdar","year":"2016","journal-title":"Cell Metab."},{"key":"B35","doi-asserted-by":"publisher","first-page":"12553","DOI":"10.1073\/pnas.1006962107","article-title":"Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK-SIRT1-PGC-1alpha pathway","volume":"107","author":"Chau","year":"2010","journal-title":"Proc Natl Acad Sci USA."},{"key":"B36","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-physiol-021115-105339","article-title":"Understanding the physiology of FGF21","volume":"78","author":"Fisher","year":"2016","journal-title":"Annu Rev Physiol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.tem.2019.05.007","article-title":"Going back to the biology of FGF21: new insights","volume":"30","author":"Lewis","year":"2019","journal-title":"Trends Endocrinol Metab."},{"key":"B38","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3389\/fcell.2016.00030","article-title":"Roles of FGFs as paracrine or endocrine signals in liver development, health, and disease","volume":"4","author":"Itoh","year":"2016","journal-title":"Front Cell Dev Biol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.cca.2019.08.005","article-title":"Fibroblast growth factor 21 in lipid metabolism and non-alcoholic fatty liver disease","volume":"498","author":"Su","year":"2019","journal-title":"Clinica Chimica Acta."},{"key":"B40","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.cmet.2016.01.006","article-title":"FGF21 lowers plasma triglycerides by accelerating lipoprotein catabolism in white and brown adipose tissues","volume":"23","author":"Schlein","year":"2016","journal-title":"Cell Metab."},{"key":"B41","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/s41598-018-37198-y","article-title":"Liver derived FGF21 maintains core body temperature during acute cold exposure","volume":"9","author":"Ameka","year":"2019","journal-title":"Sci Rep."},{"key":"B42","doi-asserted-by":"publisher","first-page":"3806","DOI":"10.1210\/jc.2017-01257","article-title":"FGF21 is an insulin-dependent postprandial hormone in adult humans","volume":"102","author":"Samms","year":"2017","journal-title":"J Clin Endocrinol Metab."},{"key":"B43","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.cmet.2015.12.008","article-title":"FGF21 regulates sweet and alcohol preference","volume":"23","author":"Talukdar","year":"2016","journal-title":"Cell Metab."},{"key":"B44","doi-asserted-by":"publisher","first-page":"28992","DOI":"10.1073\/pnas.2012073117","article-title":"Antibody-mediated activation of the FGFR1\/Klotho\u03b2 complex corrects metabolic dysfunction and alters food preference in obese humans","volume":"117","author":"Baruch","year":"2020","journal-title":"Proc Nat Acad Sci USA."},{"key":"B45","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1159\/000367943","article-title":"The single nucleotide polymorphism rs499765 is associated with fibroblast growth factor 21 and nonalcoholic fatty liver disease in a Chinese population with normal glucose tolerance","volume":"7","author":"Jiang","year":"2014","journal-title":"Lifestyle Genom."},{"key":"B46","volume-title":"A Polymorphism in the FGF21 Gene is a Novel Risk Variant for Metabolic-Associated Steatohepatitis","author":"Elsayed","year":"2020"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.cmet.2017.04.009","article-title":"FGF21 is a sugar-induced hormone associated with sweet intake and preference in humans","volume":"25","author":"S\u00f8berg","year":"2017","journal-title":"Cell Metab."},{"key":"B48","doi-asserted-by":"publisher","first-page":"345","DOI":"10.3390\/biomedicines9040345","article-title":"The effect of FGF21 and its genetic variants on food and drug cravings, adipokines and metabolic traits","volume":"9","author":"Epperlein","year":"2021","journal-title":"Biomedicines."},{"key":"B49","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.celrep.2018.03.070","article-title":"A common allele in FGF21 associated with sugar intake is associated with body shape, lower total body-fat percentage, and higher blood pressure","volume":"23","author":"Frayling","year":"2018","journal-title":"Cell Rep."},{"key":"B50","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1515\/jpem-2018-0546","article-title":"Association of the 3'UTR polymorphism (rs11665896) in the FGF21 gene with metabolic status and nutrient intake in children with obesity","volume":"32","author":"Ruiz-Padilla","year":"2019","journal-title":"J Pediatr Endocrinol Metab"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.2337\/dc16-1111","article-title":"Macronutrient intake-associated FGF21 genotype modifies effects of weight-loss diets on 2-year changes of central adiposity and body composition: the POUNDS lost trial","volume":"39","author":"Heianza","year":"2016","journal-title":"Diabetes Care."},{"key":"B52","doi-asserted-by":"publisher","first-page":"9387358","DOI":"10.1155\/2019\/9387358","article-title":"Genetic variants flanking the FGF21 gene were associated with renal function in Chinese patients with type 2 diabetes","volume":"2019","author":"Yu","year":"2019","journal-title":"J Diabetes Res."},{"key":"B53","first-page":"12","article-title":"The interaction of single nucleotide polymorphisms on fibroblast growth factor 19 superfamily genes is associated with alcohol dependence-related aggression","author":"Xu","year":"2021","journal-title":"Front Genet"},{"key":"B54","doi-asserted-by":"publisher","first-page":"e24895","DOI":"10.1371\/journal.pone.0024895","article-title":"Circulating fibroblast growth factor 21 levels are closely associated with hepatic fat content: a cross-sectional study","volume":"6","author":"Yan","year":"2011","journal-title":"PLoS ONE."},{"key":"B55","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.yexcr.2017.05.006","article-title":"Fatty liver and FGF21 physiology","volume":"360","author":"Maratos-Flier","year":"2017","journal-title":"Exp Cell Res."},{"key":"B56","doi-asserted-by":"publisher","first-page":"14578","DOI":"10.1038\/s41598-020-71569-8","article-title":"Genome-wide association study for circulating fibroblast growth factor 21 and 23","volume":"10","author":"Chuang","year":"2020","journal-title":"Sci Rep."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1053\/j.gastro.2009.01.050","article-title":"Heritability of nonalcoholic fatty liver disease","volume":"136","author":"Schwimmer","year":"2009","journal-title":"Gastroenterology."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1053\/j.gastro.2015.08.011","article-title":"Heritability of hepatic fibrosis and steatosis based on a prospective twin study","volume":"149","author":"Loomba","year":"2015","journal-title":"Gastroenterology."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/S0140-6736(18)31310-2","article-title":"Alcohol use and burden for 195 countries and territories, 1990\u20132016: A systematic analysis for the global burden of disease study 2016","volume":"392","author":"GBD","year":"2018","journal-title":"Lancet"},{"key":"B60","doi-asserted-by":"publisher","first-page":"16","DOI":"10.21037\/tgh.2019.09.08","article-title":"Epidemiology of non-alcoholic and alcoholic fatty liver diseases","volume":"5","author":"Mitra","year":"2020","journal-title":"Transl Gastroenterol Hepatol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.jhep.2013.03.007","article-title":"Global burden of alcoholic liver diseases","volume":"2013","author":"Rehm","year":"2013","journal-title":"J Hepatol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"k2817","DOI":"10.1136\/bmj.k2817","article-title":"Mortality due to cirrhosis and liver cancer in the United States, 1999\u20132016: observational study","volume":"362","author":"Tapper","year":"2018","journal-title":"BMJ."},{"key":"B63","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1053\/jhep.2002.32101","article-title":"Lower risk for alcohol-induced cirrhosis in wine drinkers","volume":"35","author":"Becker","year":"2002","journal-title":"Hepatology."},{"key":"B64","first-page":"2937","article-title":"Impact of hepatitis B and C virus infection on the clinical prognosis of alcoholic liver cirrhosis","volume":"2001","author":"Yamanaka","year":"2001","journal-title":"Anticancer Res."},{"key":"B65","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.alcohol.2004.07.008","article-title":"Alcoholic fatty liver: its pathogenesis and mechanism of progression to inflammation and fibrosis","volume":"34","author":"Lieber","year":"2004","journal-title":"Alcohol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1007\/s40211-020-00380-8","article-title":"Association of fibroblast growth factor 21 with alcohol consumption and alcohol liver cirrhosis","volume":"35","author":"Wagner-Skacel","year":"2021","journal-title":"Neuropsychiatr."},{"key":"B67","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.molmet.2018.03.010","article-title":"FGF21, a liver hormone that inhibits alcohol intake in mice, increases in human circulation after acute alcohol ingestion and sustained binge drinking at Oktoberfest","volume":"11","author":"Soberg","year":"2018","journal-title":"Mol Metab."},{"key":"B68","doi-asserted-by":"publisher","first-page":"31026","DOI":"10.1038\/srep31026","article-title":"Fibroblast growth factor 21 deficiency exacerbates chronic alcohol-induced hepatic steatosis and injury","volume":"6","author":"Liu","year":"2016","journal-title":"Sci Rep."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1016\/j.molmet.2017.08.004","article-title":"Fibroblast growth factor 21 (FGF21) is robustly induced by ethanol and has a protective role in ethanol associated liver injury","volume":"6","author":"Desai","year":"2017","journal-title":"Mol Metab."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1053\/j.gastro.2004.09.049","article-title":"The role of AMP-activated protein kinase in the action of ethanol in the liver","volume":"127","author":"You","year":"2004","journal-title":"Gastroenterology."},{"key":"B71","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.biochi.2007.09.019","article-title":"Ethanol consumption impairs regulation of fatty acid metabolism by decreasing the activity of AMP-activated protein kinase in rat liver","volume":"90","author":"Garc\u00eda-Villafranca","year":"2008","journal-title":"Biochimie."},{"key":"B72","first-page":"1778","article-title":"Therapeutic effect of fibroblast growth factor 21 on NAFLD in MSG-iR mice and its mechanism","volume":"48","author":"Zhu","year":"2013","journal-title":"Acta Pharm Sin."},{"key":"B73","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1210\/mend.14.7.0470","article-title":"Thyroid hormone regulation of hepatic genes in vivo detected by complementary DNA microarray","volume":"14","author":"Feng","year":"2000","journal-title":"Mol Endocrinol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"26687","DOI":"10.1074\/jbc.M704165200","article-title":"Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21","volume":"282","author":"Kurosu","year":"2007","journal-title":"J Biol Chem."},{"key":"B75","doi-asserted-by":"publisher","first-page":"485","DOI":"10.3389\/fendo.2018.00485","article-title":"Pathogenesis of nonalcoholic steatohepatitis and hormone-based therapeutic approaches","volume":"9","author":"Kim","year":"2018","journal-title":"Front Endocrinol (Lausanne)."},{"key":"B76","doi-asserted-by":"publisher","first-page":"5095","DOI":"10.1038\/s41598-017-05257-5","article-title":"Complementary role of fibroblast growth factor 21 and cytokeratin 18 in monitoring the different stages of nonalcoholic fatty liver disease","volume":"7","author":"Wu","year":"2017","journal-title":"Sci Rep."},{"key":"B77","doi-asserted-by":"publisher","first-page":"215","DOI":"10.14218\/JCTH.2020.00014","article-title":"NAFLD epidemiology, emerging pharmacotherapy, liver transplantation implications and the trends in the United States","volume":"8","author":"Gadiparthi","year":"2020","journal-title":"J Clin Transl Hepatol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41572-018-0014-7","article-title":"Alcoholic liver disease","volume":"4","author":"Seitz","year":"2018","journal-title":"Nat Rev Dis Prim."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1001\/jama.2019.2276","article-title":"Prevalence of alcoholic fatty liver disease among adults in the United States, 2001\u20132016","volume":"321","author":"Wong","year":"2019","journal-title":"JAMA."},{"key":"B80","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.tips.2019.12.005","article-title":"Targeting FGF21 for the treatment of nonalcoholic steatohepatitis","volume":"41","author":"Zarei","year":"2020","journal-title":"Trends Pharmacol Sci."},{"key":"B81","doi-asserted-by":"publisher","first-page":"9729107","DOI":"10.1155\/2017\/9729107","article-title":"Diagnostic value of CK-18, FGF-21, and related biomarker panel in nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"2017","author":"He","year":"2017","journal-title":"Biomed Res Int."},{"key":"B82","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/s41575-018-0014-9","article-title":"Noninvasive biomarkers in NAFLD and NASH\u2014current progress and future promise","volume":"15","author":"Wong","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1111\/1751-2980.12384","article-title":"Advances in noninvasive methods for diagnosing nonalcoholic fatty liver disease","volume":"17","author":"Shen","year":"2016","journal-title":"J Dig Dis."},{"key":"B84","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/s41401-019-0321-x","article-title":"Serum biomarkers combined with ultrasonography for early diagnosis of non-alcoholic fatty liver disease confirmed by magnetic resonance spectroscopy","volume":"41","author":"Qian","year":"2020","journal-title":"Acta Pharmacol Sin."},{"key":"B85","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1053\/j.gastro.2010.04.054","article-title":"Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease","volume":"139","author":"Dushay","year":"2010","journal-title":"Gastroenterology."},{"key":"B86","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41467-020-14384-z","article-title":"Fasting-induced FGF21 signaling activates hepatic autophagy and lipid degradation via JMJD3 histone demethylase","volume":"11","author":"Byun","year":"2020","journal-title":"Nat Commun."},{"key":"B87","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2147\/JHC.S44381","article-title":"Hepatocellular carcinoma: epidemiology and risk factors","volume":"1","author":"Kew","year":"2014","journal-title":"J Hepatocell Carcinoma."},{"key":"B88","doi-asserted-by":"publisher","first-page":"e5904","DOI":"10.1097\/MD.0000000000005904","article-title":"Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities","volume":"96","author":"Golabi","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"B89","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1097\/MCG.0b013e3182a8a793","article-title":"Trends in epidemiology, treatment, and survival of hepatocellular carcinoma patients between 1998 and 2009: an analysis of 1066 cases of a German HCC Registry","volume":"48","author":"Weinmann","year":"2014","journal-title":"J Clin Gastroenterol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"526","DOI":"10.3390\/medicina55090526","article-title":"Hepatocellular carcinoma: molecular mechanisms and targeted therapies","volume":"55","author":"Alqahtani","year":"2019","journal-title":"Medicina (Kaunas)."},{"key":"B91","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1002\/hep.26679","article-title":"Fibroblast growth factor signaling in liver carcinogenesis","volume":"59","author":"Sandhu","year":"2014","journal-title":"Hepatology."},{"key":"B92","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.3892\/etm.2018.5840","article-title":"Human fibroblast growth factor-21 serves as a predictor and prognostic factor in patients with hepatitis B cirrhosis combined with adrenal insufficiency","volume":"15","author":"Zhang","year":"2018","journal-title":"Exp Ther Med."},{"key":"B93","doi-asserted-by":"publisher","first-page":"732","DOI":"10.3889\/oamjms.2015.111","article-title":"Hepatocellular carcinoma: risk factors, diagnosis and treatment","volume":"3","author":"Janevska","year":"2015","journal-title":"Open Access Maced J Med Sci."},{"key":"B94","doi-asserted-by":"publisher","first-page":"415","DOI":"10.2147\/CEG.S173484","article-title":"study of the circulating fibroblast growth factor 21 as a novel noninvasive biomarker of hepatic injury in genotype-4 chronic hepatitis C: Egyptian patients and their response to direct-acting antiviral agents","volume":"11","author":"El Sagheer","year":"2018","journal-title":"Clin Exp Gastroenterol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.3109\/00365521.2012.694901","article-title":"Serum FGF21 and RBP4 levels in patients with chronic hepatitis C","volume":"47","author":"Kukla","year":"2012","journal-title":"Scand J Gastroenterol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.2337\/db07-1476","article-title":"Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans","volume":"57","author":"Zhang","year":"2008","journal-title":"Diabetes."},{"key":"B97","doi-asserted-by":"publisher","first-page":"4848","DOI":"10.1158\/1078-0432.CCR-20-4219","article-title":"Pharmacodynamic biomarkers predictive of survival benefit with lenvatinib in unresectable hepatocellular carcinoma: from the phase III REFLECT study","volume":"27","author":"Finn","year":"2021","journal-title":"Clin Cancer Res."},{"key":"B98","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.molmet.2018.03.002","article-title":"Deficiency of fibroblast growth factor 21 (FGF21) promotes hepatocellular carcinoma (HCC) in mice on a long term obesogenic diet","volume":"13","author":"Singhal G","year":"2018","journal-title":"Mol Metab."},{"key":"B99","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.taap.2012.08.003","article-title":"Cobalt chloride decreases fibroblast growth factor-21 expression dependent on oxidative stress but not hypoxia-inducible factor in Caco-2 cells","volume":"264","author":"Liu","year":"2012","journal-title":"Toxicol Appl Pharmacol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"153994","DOI":"10.1016\/j.metabol.2019.153994","article-title":"Fibroblast growth factor 21 in non-alcoholic fatty liver disease","volume":"101","author":"Tucker","year":"2019","journal-title":"Metabolism."},{"key":"B101","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.cmet.2013.08.005","article-title":"The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes","volume":"18","author":"Gaich","year":"2013","journal-title":"Cell Metab."},{"key":"B102","doi-asserted-by":"publisher","first-page":"e58575","DOI":"10.1371\/journal.pone.0058575","article-title":"Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319","volume":"8","author":"Kharitonenkov","year":"2013","journal-title":"PLoS ONE."},{"key":"B103","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/oby.22344","article-title":"Pegbelfermin (BMS-986036), PEGylated FGF21, in patients with obesity and type 2 diabetes: results from a randomized phase 2 study","volume":"27","author":"Charles","year":"2019","journal-title":"Obesity (Silver Spring)."},{"key":"B104","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1038\/s41591-021-01425-3","article-title":"Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial","volume":"27","author":"Harrison","year":"2021","journal-title":"Nat Med."},{"key":"B105","doi-asserted-by":"publisher","first-page":"154925","DOI":"10.1016\/j.metabol.2021.154925","article-title":"Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease","volume":"126","author":"Negi","year":"2022","journal-title":"Metabolism."},{"key":"B106","doi-asserted-by":"crossref","first-page":"Supplement_1","DOI":"10.2337\/db19-140-LB","article-title":"140-LB: NGM313, a novel activator of b-Klotho\/FGFR1c, improves insulin resistance and reduces hepatic fat in obese, nondiabetic subjects","volume":"68","author":"Depaoli","year":"2019","journal-title":"Diabetes."},{"key":"B107","doi-asserted-by":"publisher","first-page":"e57","DOI":"10.1210\/clinem\/dgab624","article-title":"LLF580, an FGF21 analog, reduces triglycerides and hepatic fat in obese adults with modest hypertriglyceridemia","volume":"107","author":"Rader","year":"2022","journal-title":"J Clin Endocrinol Metab."},{"key":"B108","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1053\/j.gastro.2014.07.044","article-title":"Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets","volume":"147","author":"Fisher","year":"2014","journal-title":"Gastroenterology."},{"key":"B109","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/MOL.0000000000000599","article-title":"Fibroblast growth factors in control of lipid metabolism: from biological function to clinical application","volume":"30","author":"Struik","year":"2019","journal-title":"Curr Opin Lipidol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1111\/dom.13023","article-title":"Once-weekly administration of a long-acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese people with hypertriglyceridaemia and in non-human primates","volume":"19","author":"Kim","year":"2017","journal-title":"Diab Obesity Metab."},{"key":"B111","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1146\/annurev-nutr-071816-064800","article-title":"Fibroblast growth factor 21: a versatile regulator of metabolic homeostasis","volume":"38","author":"BonDurant","year":"2018","journal-title":"Annu Rev Nutr."},{"key":"B112","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.ebiom.2015.05.028","article-title":"Sustained brown fat stimulation and insulin sensitization by a humanized bispecific antibody agonist for fibroblast growth factor receptor 1\/bKlotho complex","volume":"2","author":"Kolumam","year":"2015","journal-title":"EBioMedicine."},{"key":"B113","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.2337\/db10-0193","article-title":"Obesity Is a fibroblast growth factor 21 (FGF21)-resistant state","volume":"59","author":"Chui","year":"2010","journal-title":"Diabetes."},{"key":"B114","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1210\/en.2010-1262","article-title":"Lack of overt FGF21 resistance in two mouse models of obesity and insulin resistance","volume":"153","author":"Hale","year":"2012","journal-title":"Endocrinology."},{"key":"B115","doi-asserted-by":"publisher","first-page":"601349","DOI":"10.3389\/fendo.2020.601349","article-title":"FGF19 and FGF21 for the treatment of NASH-two sides of the same coin? Differential and overlapping effects of FGF19 and FGF21 from mice to human","volume":"11","author":"Henriksson","year":"2020","journal-title":"Front Endocrinol (Lausanne)."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.967375\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T01:12:53Z","timestamp":1668474773000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.967375\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,15]]},"references-count":115,"alternative-id":["10.3389\/fmed.2022.967375"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.967375","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,15]]},"article-number":"967375"}}